GC Therapeutics has appointed Kate Haviland as Board Chair. Before joining Blueprint, Kate held a series of senior leadership roles at companies including Idera Pharmaceuticals, Sarepta Therapeutics, PTC Therapeutics and Genzyme. Kate’s advisory experience includes roles as chair of the board of directors at Fulcum Therapeutics, independent director on the board of directors at Bicara Therapeutics, member of the board of directors at Biotechnology Innovation Organization (BIO) and trustee of the Boston Museum of Science. The appointment of a new Board Chair strengthens GC’s growth plans. The pipeline includes programmes centring on demyelinating neurological disorders such as multiple sclerosis (MS), as well as a regenerative cell therapy programme for the treatment of metabolic diseases such as type 1 diabetes.